MARKET

MDGL

MDGL

Madrigal Pharmac
NASDAQ
510.26
+13.23
+2.66%
Closed 19:48 05/12 EDT
OPEN
494.06
PREV CLOSE
497.03
HIGH
511.11
LOW
490.13
VOLUME
235.03K
TURNOVER
0
52 WEEK HIGH
615.00
52 WEEK LOW
265.00
MARKET CAP
11.76B
P/E (TTM)
-37.4321
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MDGL last week (0504-0508)?
Weekly Report · 2d ago
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra Blockbuster Milestone And New MASH Pipeline Deals
Simply Wall St · 2d ago
How Blockbuster Rezdiffra Sales and ARO‑PNPLA3 Licensing Will Impact Madrigal Pharmaceuticals (MDGL) Investors
Simply Wall St · 4d ago
Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays
TipRanks · 5d ago
Madrigal Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Dow Jones · 5d ago
Madrigal Pharmaceuticals Price Target Cut to $578.00/Share From $587.00 by Canaccord Genuity
Dow Jones · 5d ago
Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $578
Benzinga · 5d ago
Arrowhead Pharma swings to Q2 loss as costs rise
Reuters · 5d ago
More
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

Webull offers Madrigal Pharmaceuticals Inc stock information, including NASDAQ: MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.